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The human colon adenocarcinoma cell-line HT 29 has been shown to possess functional a*-adrenergic recep- 
tors. Here, [3H] clonidine was used as radioligand to study the evolution of az-adrenergic receptivity during 
the time course of HT 29 cell culture. Scatchard analysis of the saturation curves indicates that the number 
of [3H]clonidine binding sites increases throughout the 17 day culture period. The maximal number of a2- 
adrenoceptors is found during the stationary phase of growth, when cell density is high and mitotic rate 
low. Moreover, the use of adrenaline and clonidine as a2-adrenergic agonists reveals a relationship between 
the number of receptors and the intensity of the biological effect associated with their stimulation (inhibition 
of the VIP-induced cyclic AMP accumulation). 
a*-Adrenoceptor HT 29 cell-line [“‘H]CIonidine 
1. INTRODUCTION 
During the last decade, the hormone receptor- 
adenylate cyclase coupling system appeared to be 
more complex and dynamic than originally be- 
lieved. Indeed, several lines of evidence have in- 
dicated that the changes in adenylate cyclase activi- 
ty in response to agonist exposure could be regu- 
lated by different factors, e.g., the number of 
membrane receptors on target cells, the nucleotide 
requiring proteins which couple the receptor to the 
cyclase, the adenylate cyclase itself and the physico- 
chemical properties of the membrane (review [l]). 
This view mainly results from studies carried out 
on fi-adrenergic receptors. By contrast, only scanty 
information is available concerning the regulation 
of cuz-adrenergic receptivity. In [2], we described 
the characteristics of az-adrenoceptors on the 
adenocarcinoma cell HT 29 derived from human 
colon mucosa. This receptor, which is negatively 
coupled to the adenylate-cyclase system [3], could 
be advantageously studied in such a model for bet- 
ter understanding the az-adrenoceptor egulation. 
This work was undertaken to study the evolution 
of HT 29 cell crz-adrenoceptor equipment as a 
Cyclic AMP Catecholamines Cell culture 
function of the cell culture time course. We found: 
(i) that the number of az-adrenoceptors per mg cell 
membrane protein is a function of cell density and 
(ii) that there is a close relationship between the 
number of a2-adrenoceptors on the cell and the in- 
tensity of the biological effect associated with their 
stimulation (inhibition of the VIP-induced cyclic 
AMP accumulation). 
2. MATERIALS AND METHODS 
2.1. Materials 
The following chemicals were purchased from 
the indicated sources: [‘Hlclonidine (spec. act. 
30 Ci/mmol) from Amersham; adrenaline bitar- 
trate, bacitracin, 3-isobutylmethylxanthine (IBMX), 
ascorbic acid and EDTA from Sigma; clonidine 
hydrochloride from Boehringer-Ingelheim and the 
trypsin solution (2.5%) from Gibco. Vasoactive in- 
testinal peptide (VIP) was a generous gift from Dr 
M. Laburthe (Paris). 
2.2. Cell culture 
The HT 29 cell-line has been established in per- 
manent culture by Dr J. Fogh, from a human co- 
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lon carcinoma [4]. The cells were subcultured in 
22-cm* plastic Petri dishes (Falcon, France), as 
described in [3]. Unless otherwise stated, cell 
seeding was done from post-confluent HT 29 cells 
as follows: the cells were detached by incubating 
the cell layer for 5 min at 37°C in a phosphate buf- 
fer solution containing 0.25% trypsin and 0.5 mM 
EDTA. The cells were then collected by centrifuga- 
tion (800 x g, 10 min), resuspended in fresh 
culture medium, seeded at a density of 2.5 x lo4 
cells/cm* and grown under an sir/5% CO2 con- 
trolled atmosphere at 37°C. The culture medium 
was changed each 48 h and all experiments were 
done 24 h after the last medium change. 
Protein content in the monolayer has been 
reported to be linearly correlated with the number 
of cells per dish [4]. To verify this point under our 
experimental conditions, trypsinized detached cells 
were directly counted under a microscope. The 
results indicated that 1 mg protein represents 3.1 x 
lo6 cells at any stage of the culture and that protein 
content per dish can be used as an index of cell 
growth. 
serum-free medium to avoid interference with fetal 
calf serum components. Receptor stimulations 
were done on intact attached cells by adding 40 ~1 
drug and/or hormone solution at the appropriate 
concentration in the presence of 0.5 mM IBMX 
and 0.2% bacitracin. When adrenaline was tested, 
0.75 mM ascorbic acid was added to prevent ox- 
idation and 50 PM propranolol was added to avoid 
interference with &adrenoceptors. After 15 min at 
37”C, the medium was removed and the incuba- 
tion rapidly stopped by addition of 4 ml of 95% 
methanol/5% formic acid mixture. Cyclic AMP 
levels were measured in the evaporated methanol 
extracts by the radioimmunological method [7] us- 
ing the RIA kit from New England Nuclear. All 
reported values refer to means rt SE of 4 separate 
experiments. 
Protein content was determined using the 
brilliant blue method [8] and bovine serum albu- 
min as standard. 
3. RESULTS 
3.1. Evolution in the number of [3Hlclonidine 
2.3. Cell membrane preparation and binding binding sites 
studies 
Membrane preparation was performed as in [3]; 
protein content in the ‘membrane preparation’ was 
found to represent about 38% (range 36-41%) of 
the total cell proteins at all stages of the experi- 
ment. The saturation assays of a*-adrenoceptors 
were done according to [5], slightly modified as 
follows; to determine the total binding, 100,ul 
crude membrane preparation (2-3 mg protein/ml) 
were incubated with 300 ~1 Tris-buffer (50 mM 
Tris-HCl, 10 mM MgC12, pH 7.5) containing 
[3H]clonidine at appropriate concentrations (O-10 
nM). Non-specific binding was determined in 
parallel assays containing 10 PM unlabelled 
clonidine. After 15 min at 37”C, the incubation 
was stopped by the addition of 4 ml ice-cold Tris 
buffer. The filters were dried and counted in a,$ 
counter. The binding parameters (B,, and Kn) 
were determined from Scatchard analysis [6]. All 
binding experiments were performed at least twice. 
2.4. w-Adrenoceptor stimulation and measure- 
ment of cyclic AMP levels 
Four h before starting the experiments, the 
standard culture medium was replaced by 4 ml 
Fig.1 shows the evolution pattern of total pro- 
tein content and of the number of [‘Hlclonidine 
binding sites during HT 29 cell culture. The protein 
content curve, which reflects the cell growth, 
shows the two classical phases: the exponential 
phase (day 3 to 11) where cell divisions are rapid 
and the stationary phase (day 12 to 17) where the 
rate of cell division slackens. The determination of 
the maximum number of [‘Hlclonidine binding 
sites at saturating concentration of the ligand in- 
dicates that the number of az-adrenoceptors ex- 
pressed per mg cell membrane protein increases 
during the time course of the cell culture. This in- 
crease is especially rapid during the exponential 
phase (day 3 to 11) when the number of [3H]cloni- 
dine binding sites rises from 14 to 119 fmol/mg 
membrane protein. At the last stage of the culture, 
the number of clonidine binding sites reaches a 
plateau around 130 fmol/mg membrane protein. 
Since these experiments were done on membrane 
preparations, it is important to ensure that the 
observed increase in receptor number is not 
artefactual but reflects changes in the intact cell. 
As membrane proteins are regularly found to re- 
present about 38% of total cell proteins, it can be 
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Fig.1. Evolution of cuz-adrenoceptor number in the 
course of HT 29 cell growth in culture. The cells were 
seeded at a density of 2.5 x lo4 cells per cm2. Measure- 
ments were performed as described in section 2 on days 
3, 5, 7,9, 11, 13, 15 and 17 of culture. The total protein 
content expressed as mg per flask (+-o) and the 
number of [3H]clonidine binding sites expressed as fmol 
per mg cell membrane protein (m) are represented 
on log scales. The given values are means of 2 different 
experiments. 
Table 1 
Effects of EDTA or EDTA + trypsin treatment on 
[‘Hlclonidine binding parameters 
B max 
(fmol/mg 
membrane 
protein) 
Batch A, control 
Batch B, 0.5 mM EDTA 
Batch C, 0.5 mM EDTA + 
129 1.05 
121 1.02 
0.25% trypsin 156 1.01 
Three batches of HT 29 cells were prepared, as indicated 
in the text, from attached cells (batch A) or from 
isolated cells obtained by treatment of the cell layer with 
0.5 mM EDTA (batch B) or 0.5 mM EDTA + 0.25% 
trypsin (batch C). Binding parameters were calculated 
from Scatchard analysis 
calculated that the number of binding sites, ex- 
pressed on a per cell basis, increases from 1010 
(day 3) to 11200 (day 15). By contrast, it must be 
pointed out that the affinity of the adrenoceptors 
for the radioligand remains roughly constant (Kb 
= 0.84-l .46 nM) during the entire culture period. 
Since the petri dishes were seeded with trypsin- 
ized cells from a lZday-old cell layer, further ex- 
periments were designed to determine whether the 
action of trypsin was responsible for the loss of 
clonidine binding sites and, furthermore, to 
understand better the determinism of az-receptiv- 
ity appearance. In these experiments, 3 batches of 
crude membrane preparations were obtained from 
post-confluent cells (day 14) as follows: the first 
batch (A = control) was prepared from an attached 
frozen cell layer using neither trypsin nor EDTA, 
while batches B and C were obtained from frozen 
cells previously isolated by incubating the cell layer 
5 min at 37°C in the presence of 0.5 mM EDTA or 
0.5 mM EDTA + 0.25% trypsin, respectively. The 
[3H]clonidine binding parameters for these 3 
preparations, which are reported in table 1, clearly 
indicate that trypsinization was not responsible for 
the decrease in the number of cyz-receptors ob- 
served after seeding. 
In the experiments reported in table 2, HT 29 
trypsinized cells obtained from a 16day-old cell 
layer were seeded at densities of 0.5, 1.0, 4.0 or 
8.0 x lo6 cells per dish. Three days after seeding, 
the cell layers were frozen and membranes were 
routinely prepared; the binding study indicates 
that cuz-adrenoceptors are still present on high den- 
sity seeded cells while nearly all are lost on low 
density seeded cells. Moreover, further results 
show that there is a good correlation between the 
number of clonidine binding sites and the protein 
content in the cell layer, irrespective of the dura- 
Table 2 
Effect of cell density seeding on [3H]clonidine binding 
site number 
Seeding Total B mm 
density protein (fmol/mg (2) 
(10” cells/ (mg/dish) membrane 
dish) protein) 
0.5 0.22 14 1.2 
1 0.39 44 1.2 
4 1.75 90 1.4 
8 3.05 140 1.6 
The HT 29 cells were seeded at densities of 0.5, 1, 4 or 
8 x lo6 per dish. After 3 days of culture, membranes 
were prepared and [3H]clonidine binding parameters 
determined from Scatchard analysis 
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tion of the culture (not shown). Such results in- 
dicate that the presence of cuz-adrenoceptors on HT 
29 cells is not time dependent, but rather is a func- 
tion of cell density in the petri dish. 
3.2. Evolution of the intensity of the biological 
effect 
The last part of this work was carried out to 
determine whether the variation in the number of 
clonidine binding sites during the culture period 
was correlated with changes in the intensity of the 
cY2-receptor mediated biological effect. In these ex- 
periments, the effects of 10,uM adrenaline (plus 
50 PM propranolol) or 10 FM clonidine on the ac- 
cumulation of cyclic AMP induced by 5 nM VIP 
were studied. Under our experimental conditions, 
this VIP concentration was found to increase the 
cyclic AMP level from 8 rf: 2 to 1120 f 97 pmol/ 
mg cell proteins (not shown) which corresponds to 
a submaximal stimulation 131. The stimulations 
were done as described in section 2 on the same 
batch of dishes as those used for binding assays. 
The intensity of the biological effect, expressed as 
percent of inhibition of cyclic AMP accumulation 
as a function of the number of receptors is re- 
ported in fig.2. For both adrenaline and clonidine, 
. actnahs +propranolol cr: se4 
* clonidine ur : mt ) 
01 
50 100 150 
number of [3 HI-clcmidine bhding sites 
Fig.2 Evolution of the intensity of cuz-agonist biological 
effects as a function of HT 29 cell membrane cua-adreno- 
ceptor number. The effects of 10pM donidine and 
10pM adrenaline (plus 50pM propranolol) were tested 
on the cyclic AMP accumulation induced by 5 nM VIP. 
Results are expressed as percent of inhibition of cyclic 
AMP accumulation. Reported values are means f SE 
from 4 different experiments. 
it appears that there is a close relationship between 
the inhibition rate and the number of receptors at 
different stages of the culture. The increasing in- 
hibitory effect is not due to a decrease of VIP effi- 
ciency since the cyclic AMP accumulation induced 
by this polypeptide was fairly constant during the 
whole culture period (not shown). 
Besides, when comparing the biological poten- 
cies of clonidine and adrenahne in fig.2, it is found 
that, as previously noted f3], clonidine is only a 
partial agonist. 
Finally, it must be pointed out that there is no 
direct proportionality between the number of 
receptors and the intensity of the associated 
biological effect; the biological effect of clonidine 
or adrenaline at day 3 (22 and 38% inhibition, 
respectively) is half that found at day 17 (52 and 
86%) while the receptor number is lo-times lower 
(14 vs 130 fmol/mg membrane protein). 
4. DISCUSSION 
In [2,3] we showed the presence of cuz-adreno- 
ceptors on HT 29 cancer cells. This cell-line, estab- 
lished in permanent culture, was believed to be a 
good model for studying the regulation of the 
cuz-adrenergic receptivity as a function of the hor- 
monal and/or nutritional conditions of the cell 
culture. At present, very little is known about the 
regulation of this class of receptor. Both in vitro 
and in vivo experiments on platelets [9,10], liver 
[ll] or adipocytes [12,13) have shown that, unlike 
@receptors, cuz-adrenoceptors are not down- 
regulated after agonist exposure. However, several 
reports showed that cell a2-receptivity can vary to 
a large extent: for instance, study of the ontogeny 
of cv:adrenoceptors in rat brain indicated that 
[3H]clonidine binding rate increases rapidly during 
the first weeks after birth. Similarly, Carp& et al. 
[ 151 reported a huge increase of the a2-adrenergic 
responsiveness of hamster adipocytes during 
growth and fattening; moreover, it was shown that 
starvation and depletion of the fat stores in this 
animal induced the loss of @2-adrenoceptors and 
the disappearance of the associated antilipol~ic 
effect. 
Our results indicate that, in HT 29 cells, there is 
a significant increase in the number of&z-receptors 
during the time course of the culture; furthermore, 
we found that the receptor number is a function of 
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cell density. Unlike what was reported concerning 
platelets from patients with major depressive 
disorders [16], the increase of [3H]clonidine bind- 
ing sites in HT 29 cells is not due to a change in the 
affinity state of the receptor; indeed, the use of the 
tritiated antagonist, yohimbine, for labelling HT 
29 cell a2-adrenoceptors indicated a similar evolu- 
tion pattern for the yohimbine binding sites (un- 
published). Our work also clearly shows that there 
is a relationship between the number of receptors 
and the intensity of the biological effect associated 
to their stimulation in our model. 
At present, we have no explanation for the 
cuz-adrenoceptor maturation during the culture. 
Among the different possible mechanisms, how- 
ever, one can propose that the cu2-receptivity could 
vary according to the phases of the cell cyle, as is 
the case for @-adrenoceptors in rat glioma C6 cells 
[17]. It can be also hypothesized that membrane 
contact might be the major determinant of a2-re- 
ceptor biosynthesis. These two proposals are under 
investigation. 
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